Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (Nasdaq: EMBC) is a leading medical technology company, dedicated to developing innovative technologies, services, and solutions that advance clinical therapies for patients and enhance clinical processes for healthcare providers. The company’s core products include the BD Pyxis, PureWick, and Phasix, which have significantly impacted healthcare delivery and patient outcomes.
Embecta has recently celebrated an important milestone, marking 100 years since the development of the first syringe dedicated to insulin delivery. This heritage underscores its deep-rooted commitment to improving the lives of people with diabetes. Embecta’s global impact is further enhanced through partnerships with leading advocacy and professional groups, striving to raise awareness and provide better solutions for diabetes care.
Financially, Embecta has shown robust performance, consistently demonstrating strong revenue growth. The company's Board of Directors recently declared a quarterly cash dividend of $0.15 per share, payable on September 13, 2023. Embecta regularly evaluates its financial results on both a reported and Constant Currency basis to provide a clear picture of its operational performance, excluding the effects of currency fluctuations.
Embecta continues to spearhead significant projects and initiatives. For instance, its recent symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference showcased the company’s commitment to innovative insulin pump therapies for type 2 diabetes. Furthermore, Embecta has been proactive in responding to regulatory requirements like the EU MDR and GDPR, ensuring compliance while continuously improving its products and services.
With approximately 2,000 dedicated employees worldwide, Embecta leverages its rich legacy and innovative spirit to empower people with diabetes to live their best lives. Through strategic partnerships and a relentless focus on quality and reliability, Embecta remains at the forefront of diabetes care.
Embecta (Nasdaq: EMBC) has announced its participation in the upcoming J.P. Morgan Global Leveraged Finance Conference in Miami. The company's Chief Financial Officer, Jake Elguicze, is scheduled to deliver a presentation on Tuesday, February 25, 2025, at 3:00 p.m. ET.
Embecta Corp. (EMBC) reported Q1 FY2025 financial results with revenues of $261.9 million, down 5.6% on a reported basis. The company experienced declines in both U.S. (down 4.6%) and International revenues (down 6.6%). Adjusted earnings per diluted share were $0.65, compared to $0.61 in the prior year period.
The company is updating its FY2025 guidance, adjusting revenue outlook due to foreign exchange assumptions while raising expectations for certain key financial metrics. The restructuring plan related to the discontinuation of the insulin patch pump program remains on track for completion by the end of H1 FY2025.
Key financial metrics include adjusted EBITDA of $97.3 million with a 37.2% margin, and the declaration of a $0.15 per share quarterly dividend. The company maintains strong liquidity with $216.7 million in cash and equivalents, while managing $1.569 billion in debt principal.
Embecta (Nasdaq: EMBC) has announced that its Board of Directors has declared a quarterly cash dividend of $0.15 per share for each issued and outstanding share of the company's common stock. The dividend will be paid on March 14, 2025, to stockholders who are on record at the close of business on February 28, 2025.
Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced it will host a conference call to discuss its fiscal first quarter 2025 financial results on Thursday, February 6, 2025, at 8:00 a.m. Eastern Time. The event will include an operational update and a Q&A session.
Participants can access the live webcast through the company's investor relations website at investors.embecta.com. A replay of the webcast will be available starting at 11:00 a.m. ET on the same day and will remain accessible on the website for one year.
Embecta (Nasdaq: EMBC) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Interested parties can access the audio webcast of the presentation through the 'News & Events' section on Embecta's investor relations website at investors.embecta.com.
Embecta Corp. (EMBC) reported Q4 FY2024 results with revenues of $286.1M, up 1.5%. The company announced significant strategic changes including discontinuing its insulin patch pump program and initiating a restructuring plan expected to generate annual pre-tax savings of $60-65M. The restructuring will incur total pre-tax charges of $35-45M in FY2025. For FY2024, total revenues were $1,123.1M, up 0.2%, with net income of $78.3M. The company provided FY2025 guidance with expected revenues of $1,093-1,110M and adjusted EPS of $2.70-2.90.
Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share of common stock. The dividend will be paid on December 18, 2024 to stockholders of record as of the close of business on December 6, 2024.
Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced it will host a conference call on November 26, 2024, at 8:00 a.m. ET. The call will cover the company's fiscal fourth quarter and full year 2024 financial results, along with an operational update and preliminary fiscal year 2025 financial guidance. Investors can access the event via live webcast or teleconference, with a replay available from 11:00 a.m. ET on the same day through the company's investor relations website for one year.
Embecta (Nasdaq: EMBC) has announced it will host a conference call on Thursday, November 26, 2024, at 8:00 a.m. ET to discuss its fiscal fourth quarter and full year 2024 financial results. The global diabetes care company will also provide an operational update and preliminary fiscal year 2025 financial guidance. Participants can access the event via live webcast or teleconference. A replay will be available from 11:00 a.m. ET on November 21, 2024, through the company's investor relations website for one year.
Embecta (Nasdaq: EMBC) is set to ring the Nasdaq Closing Bell in recognition of National Diabetes Awareness Month, joined by multiple diabetes advocacy and professional groups. The ceremony celebrates the company's 100-year legacy in diabetes care, dating back to 1924 when they developed the world's first insulin-specific syringe.
With approximately 537 million people worldwide living with diabetes, Embecta continues its commitment to improving lives through innovative solutions, partnerships, and education. The event, which will be streamed live on Nasdaq's Facebook page, brings together organizations including ADCES, Beyond Type 1, Camp Nejeda, and The diaTribe Foundation to raise awareness and support for the diabetes community.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
What does Embecta Corp. specialize in?
What are some of Embecta's key products?
How long has Embecta been involved in diabetes care?
What recent financial milestone has Embecta achieved?
How does Embecta report its financial results?
What strategic initiatives is Embecta currently focusing on?
How does Embecta contribute to diabetes awareness?
Where are Embecta's main manufacturing operations located?
How does Embecta support its workforce?
What is the significance of Embecta's recent symposium at ATTD?
